Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?

Summary

Article discusses Roche's obesity drug and its potential to compete with Eli Lilly and Novo Nordisk in the obesity treatment market. The article contains only a headline and image with no substantive clinical or financial data provided.